Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGPL1 | O95470 | 4/20 | 0.63 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.54 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.50 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.50 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.50 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.50 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273298 | 1.00 | SGPL1 (0.63) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL13030814 | 0.98 | SGPL1 (0.66) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL8934971 | 0.98 | SGPL1 (0.66) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL8776459 | 0.89 | S1PR4 (0.59) | SGPL1LPAR5LPAR3LPAR1LPAR2 | |
| SCHEMBL31395563 | 0.86 | PGD (0.52) | SGPL1PLA2G4ALPAR5 | |
| SCHEMBL28480885 | 0.83 | LPAR5 (0.65) | SGPL1PLA2G4ALPAR5LPAR3LPAR1 | |
| SCHEMBL18286333 | 0.83 | SGPL1 (0.61) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL43371 | 0.83 | SGPL1 (0.61) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL195872 | 0.83 | SGPL1 (0.61) | SGPL1PLA2G4APTPN1LPAR5LPAR3 | |
| SCHEMBL10658217 | 0.82 | SGPL1 (0.56) | SGPL1PLA2G4APTPN1LPAR5LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225753-A | Preparation method of (R) -1, 2-di-fatty acyl-sn-glycerol-3-phosphoric acid | 苏州昊帆生物股份有限公司 | 2021-01-15 | — | — | CN | claimed |
| WO-2011034397-A2 | METHOD FOR PREDICTING DRUG TARGETS AND SCREENING FOR DRUGS FOR PATHOGENIC MICROORGANISMS USING ESSENTIAL METABOLITES | 한국과학기술원 (KR) | 2011-03-24 | — | — | WO | claimed |
| EP-1615937-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | University of Utah Research Foundation (US) | 2006-01-18 | — | — | EP | claimed |
| WO-2004092188-A2 | ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2004-10-28 | — | — | WO | claimed |
| CN-117915929-A | Engineered Natural Killer (NK) cells and related methods | 因达普塔治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3931301-A1 | LIPID BIOSYNTHESIS AND ABIOTIC STRESS RESILIENCE IN PHOTOSYNTHETIC ORGANISMS | Board of Trustees of Michigan State University (US) | 2022-01-05 | — | — | EP | disclosed |
| CN-112225753-A | Preparation method of (R) -1, 2-di-fatty acyl-sn-glycerol-3-phosphoric acid | 苏州昊帆生物股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-112225753-A | Preparation method of (R) -1, 2-di-fatty acyl-sn-glycerol-3-phosphoric acid | 苏州昊帆生物股份有限公司 | 2021-01-15 | — | — | CN | disclosed |
| EP-2463654-B1 | Compositions and methods for modeling saccharomyces cerevisiae metabolism | UNIV CALIFORNIA (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3602062-A1 | TISSUE-DERIVED EXTRACELLULAR VESICLES AND THEIR USE AS DIAGNOSTICS | Lötvall, Jan (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018171947-A1 | TISSUE-DERIVED EXTRACELLULAR VESICLES AND THEIR USE AS DIAGNOSTICS | LOETVALL JAN (US) | 2018-09-27 | — | — | WO | disclosed |
| EP-3356539-A1 | TRIGLYCERIDE OILS HAVING ASYMMETRIC TRIGLYCERIDE MOLECULES | Corbion Biotech, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2002000857-A9 | 53320, A HUMAN ACYLTRANSFERASE AND USES THEREFOR | MILLENNIUM PHARM INC (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002020801-A2 | 26199, 33530, 33949, 47148, 50226, AND 58764, HUMAN TRANSFERASE FAMILY MEMBERS AND USES THEREFOR | MILLENNIUM PHARMACEUTICALS INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002000857-A2 | 53320, A HUMAN ACYLTRANSFERASE AND USES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001064864-A2 | SINGLE-STRANDED NUCLEIC ACID TEMPLATE-MEDIATED RECOMBINATION AND NUCLEIC ACID FRAGMENT ISOLATION | MAXYGEN, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-0991770-A2 | PROSTATE CANCER GENE | GENSET (FR) | 2000-04-12 | — | — | EP | disclosed |
| WO-1999032644-A2 | PROSTATE CANCER GENE | GENSET (FR) | 1999-07-01 | — | — | WO | disclosed |
| EP-0674529-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | NeXstar Pharmaceuticals, Inc. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013324-A1 | LIPID PRODRUGS FOR ORAL ADMINISTRATION | VESTAR, INC. (US) | 1994-06-23 | — | — | WO | disclosed |